Bio-Techne Corp
$ 57.36
-1.93%
16 Apr - close price
- Market Cap 8,974,161,000 USD
- Current Price $ 57.36
- High / Low $ 58.47 / 56.80
- Stock P/E 108.23
- Book Value 12.90
- EPS 0.53
- Next Earning Report 2026-05-06
- Dividend Per Share $0.32
- Dividend Yield 0.55 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.04 %
- 52 Week High 72.06
- 52 Week Low 45.74
About
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$72.27
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-10-30 | 2024-08-07 | 2024-05-01 | 2024-02-01 | 2023-10-31 | 2023-08-08 | 2023-05-03 |
| Reported EPS | 0.46 | 0.42 | 0.53 | 0.56 | 0.42 | 0.42 | 0.49 | 0.48 | 0.4 | 0.41 | 0.55 | 0.53 |
| Estimated EPS | 0.43 | 0.43 | 0.5 | 0.51 | 0.39 | 0.38 | 0.49 | 0.45 | 0.41 | 0.44 | 0.55 | 0.53 |
| Surprise | 0.03 | -0.01 | 0.03 | 0.05 | 0.03 | 0.04 | 0 | 0.03 | -0.01 | -0.03 | 0 | 0 |
| Surprise Percentage | 6.9767% | -2.3256% | 6% | 9.8039% | 7.6923% | 10.5263% | 0% | 6.6667% | -2.439% | -6.8182% | 0% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.48 |
| Currency | USD |
Previous Dividend Records
| Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Jan 1970 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-02-27 | 2025-11-28 | 2025-08-29 | 2025-05-30 | 2025-02-28 | None | 2024-11-22 | 2024-08-30 | 2024-05-24 | 2024-02-26 |
| Amount | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TECH
2026-04-17 07:38:30
Bio-Techne Corporation has introduced a new streamlined brand architecture with three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. This restructuring aims to help scientists and clinicians more easily find solutions aligned with the scientific journey from early discovery to clinical decision-making. The new brands will debut at upcoming scientific meetings, including the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™.
2026-04-17 03:47:29
Bio-Techne Corporation has unveiled a streamlined brand architecture to help scientists and clinicians more easily access their solutions. The company has organized its vast portfolio under three main brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, aligning its offerings from early discovery through translational insights to clinical diagnostics. This restructuring aims to empower scientific discovery, advance translational research, and provide reliable diagnostic tools, thereby accelerating scientific progress and improving patient outcomes.
2026-04-16 21:38:20
Bio-Techne Corporation has launched a new, streamlined brand architecture, organizing its products and technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. This restructuring aims to align with the scientific journey from early discovery to clinical diagnostics, making it easier for scientists and clinicians to find relevant solutions. The new brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™.
2026-04-16 20:38:28
Bio-Techne has unveiled a new brand architecture, organizing its solutions into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. This restructuring aims to streamline how scientists and clinicians access solutions, aligning with the progression from early discovery to clinical decision-making. The company believes this will strengthen its position as a scientific partner and accelerate scientific and clinical progress.
2026-04-16 20:19:24
Bio-Techne's CEO, Kim Kelderman, exercised 36,500 stock options at $47.60 per share, converting them into common shares. To cover tax obligations, 32,088 shares were withheld at a price of $58.66 per share. Following these transactions, Kelderman directly owns 53,077 common shares and retains substantial unexercised stock options and restricted stock units.
2026-04-16 17:18:00
Bio-Techne Corp. (TECH) shares fell by 1.93% on Thursday, closing at $57.36, despite a generally positive trading day for the broader market. This marked the second consecutive day of losses for the stock, while the S&P 500 and Dow Jones Industrial Average both saw gains.
